Metformin for aging and cancer prevention

Vladimir N. Anisimov

Department of Carcinogenesis and Oncogerontology, N.N. Petrov Research Institute of Oncology, St.Petersburg 197758, Russia

Key words: metformin; biguanides; life span, aging; cancer prevention
Received: 10/29/10; accepted: 11/09/10; published on line: 11/11/10
Corresponding author: V.N. Anisimov, PhD; E-mail: aging@mail.ru
Copyright: © Anisimov. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Abstract: Studies in mammals have led to the suggestion that hyperglycemia and hyperinsulinemia are important factors in aging. Insulin/insulin-like growth factor 1 (IGF-1) signaling molecules that have been linked to longevity include daf-2 and InR and their homologues in mammals, and inactivation of the corresponding genes increases life span in nematodes, fruit flies and mice. It is possible that the life-prolonging effect of caloric restriction is due to decreasing IGF-1 levels. Evidence has emerged that antidiabetic drugs are promising candidates for both life span extension and prevention of cancer. Thus, antidiabetic drugs postpone spontaneous carcinogenesis in mice and rats, as well as chemical and radiation carcinogenesis in mice, rats and hamsters. Furthermore metformin seems to decrease cancer risk in diabetic patients.

INTRODUCTION

The effects of factors or drugs that increase life span (geroprotectors) on spontaneous tumor development may provide important clues to the interactions of aging and carcinogenesis. A number of substances were suggested as life span extension means [1-3]. Being suggested on the current knowledge on factors and mechanisms or theories of aging these pharmacological interventions in the aging process sometime were followed some unfavorable effects. The comparison of the data on the mechanisms of action of geroprotectors with its influence on the development of spontaneous and experimentally induced tumors permits to deepen our understanding of interactions between two fundamental biological processes - aging and carcinogenesis [1,2,4]. The main goal of this review is critical evaluation of available data on effects of antidiabetic drugs on aging development in experimental animals and perspectives of practical use of the drugs for cancer prevention and enhance of healthy aging in humans.

Calorie restriction (CR) is the only known intervention in mammals that has been shown consistently to increase life span, reduce incidence and retard the onset of age-related diseases, including cancer and diabetes. CR has also been shown to increase the resistance to stress and toxicity, and maintain function and vitality in laboratory mammals of younger ages [3,5-7]. Studies in CR rhesus monkeys have produced physiological responses strikingly similar to those observed in rodents [3,8,9]. Emerging data from these studies suggest that long-term CR will reduce morbidity and mortality in primates, and thus may exert beneficial “anti-aging” effects in humans [3,8-11]. It is worthy to note that alongside with point of view that CR can work for human beings, there are authors who believe that to early to decide it or CR cannot work for human beings [3,12-19].

The crucial event of the action of CR is the reduction in the levels of insulin and insulin-like growth factor-1 (IGF-1) and also increases insulin sensitivity in rodents [5,12] as well as in monkeys [9]. In C. elegans and D. melanogaster, the mutation modification of genes operating in the signal transduction from insulin receptor to transcription factor daf-16 (age-1, daf-2, InR, etc.) are strongly associated with longevity [10,19,20]. Whole-genome analysis of gene expression...
during aging of nematode worm *C. elegans* provided new evidence on the role of insulin homologue genes and SIR2 homologues in longevity by interacting with the daf-2/age-1 insulin-like signaling pathway and regulating downstream targets [21].

Activity of *daf-16* counteracts both aging and tumor growth in *C. elegans*. These two processes are linked in nature, because tumor rates invariably rise as an animal ages. Pinkston-Gosse and Kenyon [22] have identified 29 *daf-16/FoxO*-regulated genes that act in the insulin/IGF-1 pathway to influence *C. elegans* tumor growth. Some of these genes are required for the entire effect that *daf-2* mutations have on cell death, but none appear to be required for the entire effect on cell division. Because both increased apoptosis and reduced cell proliferation contribute to the tumor-protective effects of *daf-2* mutations [23], together there downstream genes are likely to act in a cumulative fashion to influence tumor growth, much as downstream targets of *daf-16* appear to act cumulatively to influence lifespan [24]. It was shown that almost half of the genes that affect tumor growth also affect the lifespan of animals that do not have tumors, indicating that the ability of the insulin/IGF-1 pathway to couple longevity and tumor resistance extends downstream of DAF-16 [21].

*DAF-2* and *InR* are structural homologues of tyrosine kinase receptor in vertebrata that includes the insulin receptor and the IGF-1 receptor. It was shown that in vertebrata the insulin receptor regulates energy metabolism whereas IGF-1 receptor promotes a growth. During last years series of elegant experiments in mice and rats in which this or that key elements of the insulin/IGF-1 signaling pathway were genetically modified provide an evidence of the involvement of the system in the control of mammalian aging and longevity [25]. Recently it was shown that in mice, less insulin receptor substrate-2 (Irs2) signaling throughout the body or just in the brain extended life span up to 18% [26]. Kapeller et al. [27] showed that partial inactivation of brain IGF receptors (IGF-1R) in embryonic brain selectively inhibited GH and IGF-1 pathways after birth. This causes growth retardation, smaller adult size, and metabolic alterations, and led to delayed mortality and longer mean life span. The mean life span in bIGF1RKO mice was increased by 9.3% (p<0.05) as compared with control mice, and tumor incidence was 44% and 53%, correspondingly (p>0.05).

Selman et al. [28] measured the life span of mice lacking either insulin receptor substrate (IRS) 1 or 2, the major intracellular effectors of the insulin/IGF-1 signaling (IIS) receptors. It was observed that female *Irs1*+/− mice are long-lived. Furthermore, they displayed resistance to a range of age-sensitive markers of aging including skin, bone, immune, and motor disfunction. These improvement in health were seen despite mild, lifelong insulin resistance. Thus, enhanced insulin sensitivity is not a prerequisite for IIS. *Irs1*+/− female mice also displayed normal anterior pituitary function, distinguishing them from long-living somatotrophic axis mutants. In contrast, *Irs2*+/− mice were short-lived, whereas *Irs1*+/+ and *Irs2*+/− mice of both sexes showed normal life spans.

It was shown that the incidence of mutations in insulin regulatory region (IRE) of APO C-III T-455 C directly correlates with longevity in humans. This is the first evidence showing that mutation located downstream to *daf-16* in insulin signal transduction system is associated with longevity [29]. It is worth noting that centenarians display lower degree of resistance to insulin and lower degree of oxidative stress as compared with elderly persons before 90 years [30,31]. The authors suggest that centenarians may have been selected for appropriate insulin regulation as well as for the appropriate regulation of tyrosine hydroxylase (TH) gene, whose product the rate is limiting in the synthesis of catecholamines, stress-response mediators. It was shown that catecholamine may increase free radical production through induction of the metabolic rate and auto oxidation in diabetic animals [32]. A study on aging parameters of young (up to 39) and old (over 70) individuals having similar IGF-1 serum levels provides evidence of important role of this peptide for life potential [33]. Roth et al. [34] analyzed data from the Baltimore Longitudinal Study of Aging and reported that survival was greater in men who maintained lower insulin level. In women, genetic variation causing reduced insulin/IGF-1 signaling pathway activation is beneficial for old age survival [35].

Hyperglycemia is an important aging factor involved in generation of advanced glycosylation end products (AGEs) [36-38]. Untreated diabetics with elevated glucose levels suffer many manifestations of accelerated aging, such as impaired wound healing, cataracts, vascular and microvascular damage [39]. The accumulation of the AGE, pentosidine, is accelerated in diabetic animals [32]. A study on aging parameters of young (up to 39) and old (over 70) individuals having similar IGF-1 serum levels provides evidence of important role of this peptide for life potential [33]. Roth et al. [34] analyzed data from the Baltimore Longitudinal Study of Aging and reported that survival was greater in men who maintained lower insulin level. In women, genetic variation causing reduced insulin/IGF-1 signaling pathway activation is beneficial for old age survival [35].
effects similar to CR. Reviewing the available data on the benefits and adverse effects of CR and genetic modifications, Longo and Finch [52] suggested three categories of drugs which may have potential to prevent or postpone age-related diseases and extend life span: drugs that (i) stimulate dwarf mutations and therefore decrease pituitary production of growth hormone (GH); (ii) prevent IGF-1 release from the liver, or (iii) decrease IGF-1 signaling by the action on either extracellular or intracellular targets.

The antidiabetic drugs, phenformin (1-phenylethylbiguanide), buformin (1-butybiguanide hydrochloride) and metformin (N,N-dimethylbiguanide) were observed to reduce hyperglycemia, improve glucose utilization, reduce free fatty acid utilization, gluconeogenesis, serum lipids, insulin, IGF-1, reduce body weight and decrease metabolic immunodepression both in humans and rodents [39,40,53,54]. Nowadays, phenformin is not used in clinical practice due to its side effects (mainly lactic acidosis) observed in patients with non-compensated diabetes. It is worthy of note that during more than 10-year-long experience of administration of phenformin to patients without advanced diabetes Vladimir M. Dilman and Lev M.Berstein [55-61] observed no cases of lactic acidosis or any other side effects. We believe that the analysis of results of long-term administration of this drug as well as another antidiabetic biguanides (buformin and metformin) to non-diabetic animals is seems very important for understanding of links between insulin and longevity on the one hand and between insulin and cancer on the other hand.

**Biguanides and Life Span**

Fourty years ago, it was suggested to use biguanides as a potential anti-aging treatment [39,62]. There are data on effect of the drugs on life span in worms, mice and rats. Buformin was supplemented to nutrient medium in various concentrations (from 1.0 to 0.00001 mg/ml) during the larvae stage and over the life span of *C. elegans*. The drug given at the concentration of 0.1 mg/ml increased the mean life span of the worms by 23.4% (p < 0.05) and the maximum life span by 26.1% as compared to the controls [63]. Metformin supplementation (50 mM dose) was shown to increase the mean life span, but not maximum, of *C. elegans*, although 10 or 100 mM doses showed no significant life span benefit [64]. The authors have shown that metformin prolongs nematode healthspan, slowing lipofuscin accumulation, extending mean life span, and prolonging youthful locomotor ability in a dose-dependent manner. Genetic data suggest the metformin acts through a mechanism similar to that operative in eating-impaired CR mutants, but independent of insulin signaling pathway. Energy sensor AMPK and AMPK-activating kinase LKB1, which are activated in mammals by metformin treatment [65,66], are essential for health benefits in *C. elegans*, suggesting that metformin engages a metabolic loop conserved across phyla [64]. It was also shown metformin activated SKN-1/Nrf2, oxidative stress-responsive transcription factor.

The available data on effect of antidiabetic biguanides on life span in mice and rats are summarized in the Table 1. Female C3H/Sn mice were kept from the age of 3.5 months at standard ad libitum diet were given phenformin 5 times a week orally at a single dose 2 mg/mouse until a natural death [67]. The treatment with phenformin prolonged the mean life span of mice by 21% (p < 0.05), the mean life span of last 10% survivors by 28% and the maximum life span by 5.5 months (by 26%) in comparison with the control. At the time of death of the last mice in the control group 42% of phenformin-treated mice were alive. In this study food consumption in control and drug-exposed groups was not measured.

Phenformin was given 5 times a week to female outbred LIO rats starting from the age of 3.5 month until a natural death in a single dose of 5 mg/rat/day orally [1,73]. Administration of phenformin failed to influence the mean life span in rats. At the same time, the mean life span of the last 10% survivors was increased by 10% (p < 0.005), and maximum life span was increased by 3 months (+ 10%) in comparison with the controls. The treatment with phenformin slightly decreased the body weight of rats in comparison with the control (p > 0.05). The disturbances in the estrus function observed in 36% of 15-16-month old rats of the control group and only in 7% of rats in phenformin-treated group (p < 0.05).

Buformin was given 5 times a week to female LIO rats starting from the age of 3.5 month until a natural death in a single dose of 5 mg/rat/day orally [73,74]. The treatment slightly increased mean life span of rats (by 7%; p > 0.05). The mean life span of the last 10% survivors increased by 12% (p < 0.05) and the maximum life span increased by 2 months (+5.5%) as compared with controls. The body weight of rats treated with buformin was slightly (5.2 to 9.4%) but statistically significantly (p < 0.05) decreased in comparison with the control from the age of 12 months to 20 months (p < 0.05). At the age of 16-18 months 38% of control rats revealed the disturbances in the estrus cycle persistent estrus, repetitive pseudo-pregnancies or anestrous), whereas in females treated
with buformin these disturbances were observed only in 9% of rats (p < 0.05). Again, in both these studies food consumption in control and drug-exposed groups was not measured.

Long-term administration of metformin (100 mg/kg in drinking water) slightly decreased the food consumption but did not changed the body weight or temperature, slowed down the age-related rise in blood glucose and triglycerides level, as well as the age-related switch-off of estrous function, prolonged the mean life span by 8% (p < 0.05), the mean life span of last 10% survivors by 13.1%, and the maximum life span by 1 month in transgenic HER-2/neu mice in comparison with the control animals [68]. The demographic aging rate represented by the estimate of respective Gompertz’s parameter was decreased 2.26 times. The reduction of the serum level of cholesterol and beta-lipoproteins was observed in metformin-treated transgenic HER-2/neu female mice [68]. Metformin treatment decreased the food consumption in these mice at the age of 4 and 6 months, suggesting that “voluntary CR” may be the source of the effects of metformin [3]. In our new experiment metformin was given to male and female 129/Sv mice [72]. It was observed slight increase in mean and maximum life span in females but reduction of the mean life span by 13.4% in males.

### Table 1. Effect of antidiabetic drugs on life span in mice and rats

| Strain  | Sex  | Treatment | No. of animals | Life span, days | References |
|---------|------|-----------|----------------|----------------|------------|
|         |      |           |                | Mean           | Last 10% of survivors | Maximum |
| Mouse   |      |           |                |                |                  |          |
| C3H/Sn  | Female | Control   | 30             | 450 ± 23.4     | 631 ± 11.4          | 643      |
|         |       | Phenformin| 24             | 545 ± 39.2 (+21.1%) | 810 ± 0 * (+28.4%) | 810 (+26%) |
| FVB/N   | Female | Control   | 34             | 264 ± 3.5      | 297 ± 7.3           | 311      |
|         |       | Metformin | 32             | 285 ± 5.2 (+8.0%) | 336 ± 2.7 (+13.1%)*| 340 (+16.2%) |
| FVB/N   | Female | Control   | 15             | 285 ± 12       | 396 ± 0             | 396      |
|         |       | Metformin | 20             | 304 ± 10       | 352 ± 7             | 359      |
| SHR     | Female | Control   | 50             | 388 ± 29.2     | 727 ± 22.5          | 814      |
|         |       | Metformin | 50             | 535 ± 31.9* (+37.9%) | 878 ± 6.6* (+20.8%) | 898 (+10.3%) |
| NMRI    | Female | Control   | 50             | 346 ± 11.9     | 480 ± 9.2           | 511      |
|         |       | Diabenol  | 50             | 369 ± 12.9     | 504 ± 6.4* (+5.9%)  | 518      |
| 129/Sv  | Male  | Control   | 41             | 662 ± 27.7     | 951 ± 32.3          | 1029     |
|         |       | Metformin | 46             | 573 ± 26.5 (-13.4%)* | 931 ± 30.4         | 1044     |
| 129/Sv  | Female | Control  | 47             | 706 ± 20.8     | 910 ± 8.9           | 930      |
|         |       | Metformin | 48             | 742 ± 16.3 (+5.1%) | 913 ± 19.2         | 966 (+3.9%) |
| Rat     | Female | Control   | 41             | 652 ± 27.3     | 885 ± 11.3          | 919      |
|         |       | Phenformin| 44             | 652 ± 28.7     | 974 ± 16.2* (+10.1%)| 1009 (+9.8%) |
|         | Female | Control   | 74             | 687 ± 19.2     | 925 ± 22.5          | 1054     |
|         |       | Buformin  | 42             | 737 ± 26.4 (+7.3%) | 1036± 38.9* (+12%) | 1112 (+5.5%) |
| Fischer-344 | Male | Control | 31             | 796 ± 170      | 1039 ± 29.6         | 1065     |
|         |       | Metformin | 40             | 815 ± 186      | 1061 ± 2.5          | 1062     |

The difference with control is significant: * - p < 0.05 ; ** p < 0.01 (Student’s test)
The chronic treatment of female outbreed SHR mice with metformin (100 mg/kg in drinking water) slightly modified the food consumption but decreased the body weight after the age of 2 months (p<0.01), increased the mean life span of last 10% survivors by 20.8% (p<0.01), and maximum life span by 2.8 months (+10.3%) in comparison with the control SHR mice [700]. The treatment with metformin failed to influence blood estradiol concentration and spontaneous tumor incidence in female SHR mice.

Transgenic mice with Huntington's disease (HD) (the R6/2 line expressing exon 1 of the huntington protein including ~130 glutamine repeats) were given metformin in drinking water (2 or 5 mg/ml) starting from the age of 5 weeks [76]. Metformin treatment significantly prolonged (by 20.1%) the survival time of male (but not female) HD mice at the 2 mg/ml dose (~300 mg/kg/day) without affecting fasting blood glucose level. This dose of the drug also decreased hind limb clamping time in 11-week-old mice. The higher dose of metformin did not prolong life span, and neither dose was effective in female HD mice.

In the study of Smith et al. [75], six month old male F344 rats were randomized to one of four diet: control, calorie restricted (CR), metformin (300 mg/kg/day) and pair fed to metformin. The CR group had significantly reduced food intake and body weight throughout the study. Body weight was significantly reduced in the metformin group compared with control during the middle of the study, despite similar weekly food intake. There were no significant differences in the mean life span or the mean of the last surviving 10% of each group in the CR, metformin and pair fed groups compared with control. However, the aging rate estimate (α – slope, rate of increase of mortality) of the Gompertz model of the control group alone was significantly different from the three other groups, reflecting the early deaths in the CR, metformin and pair fed groups. CR significantly increased life span in the 25th quantile but not the 50th, 75th, or 90th quantile. The groups of rats exposed to metformin or to the pair feeding were not significantly different from controls at any quantile [75]. The authors stressed the one limitation of this study – the lack of a robust CR response for extension of maximum life span which has been observed in another the CR study using the same strain of rats [19]. The reduced efficacy of CR in this study might provide a partial explanation for the lack of a significant increase with metformin treatment. In addition to the dampened CR response, metformin treatment did not significantly affect glucose/insulin levels in this study. The metformin concentration utilized in the diet is approximately 10 times that of the highest dose used in human treatments, implying that any increase necessary to observe life span benefits is questionable for a human application [75].

There are only few data on the effect of other than biguanides antidiabetic drugs on life span of animals. The effects of new antidiabetic drug Diabenol® (9-β-diethyl-aminoethyl-2,3-dihydro-imidazo-(1, 2-a) benzimidazol dihydrochloride) on life span of NMRI and transgenic HER-2/neu mice have been studied [71]. Diabenol was synthesized in Rostov State University and its hypoglycemic activity was evaluated as 1.5 times more effective than of maninil (glibenclamide) and equal to the effect of glyclazide (pioglitazone) in rats, rabbits and dogs [77,78]. Diabenol restores increases tissue susceptibility to insulin and extends hypoglycemic effect of the hormone. It increases glucose utilization in glucose loading test in the old obese rats. It was suggested that diabenol influence insulin receptors in peripheral tissues. Diabenol increases uptake of glucose by isolated rat diaphragm in vitro both without supplementation of insulin into the medium or with supplemented insulin. Diabenol also decreases platelet and erythrocyte aggregation and blood viscosity, inhibits mutagenic effect of 2-acetylaminofluorene and has antioxidant activity [77,79,80]. It is shown that treatment with the drug failed influence body weight gain dynamics, food and water consumption and the body temperature, slowed down age-related disturbances in estrous function and increased life span of all and 10% most long-living NMRI mice [71]. Diabenol treatment slowed down age-related changes in estrous function in HER-2/neu mice, failed influence survival of these mice.

Thus, available data gives evidence that antidiabetic drugs in some cases can increase survival of rodents (Table 1). This effect was not observed in all experiments and varied depending on strain and species of animals. Female mice and rats have been treated in the majority of these studies. The experiments with males of different strains will be useful for conclusion on geroprotective potential of antidiabetic biguanides. Metformin is now a widely prescribed medication for treating type 2 diabetes. In addition to improving the metabolic profile of diabetes, increased survival from all-cause mortality has been associated with metformin treatment in both diabetic and cardiovascular disease patients [81,82].

**Biguanides and Endocrine System**

Parameters of reproductive function are among most valuable biomarkers of aging [83]. The treatment with phenformin decreased hypothalamic threshold of the
sensitivity to feedback inhibition by estrogens [84,85], which is one of the most important mechanisms regulating age-related decline and switch-off of the reproductive function [39,62,86,87]. It is worthy of note that another antidiabetic biguanide, metformin, may improve menstrual regularity, leading to spontaneous ovulation, and enhance the induction of ovulation with clomiphene citrate in women with polycystic ovary syndrome [88,89]. The treatment with phenformin also decreased hypothalamic threshold sensitivity to feedback regulation by glucocorticoids and by metabolic stimuli (glucose and insulin) [39]. It was recently shown that elements involved in the insulin/IGF-1 signaling pathway are regulated at the expression and/or functional level in the central nervous system. This regulation may play a role in the brain’s insulin resistance [90], in the control of ovarian follicular development and ovulation [91], and brain’s control of life span [92,93]. Antidiabetic biguanides also alleviated age-related metabolic immunodepression [39,40]. These mechanisms can be involved in geroprotective effect of biguanides.

Treatment with chromium picolinate which elevated the insulin sensitivity in several tissues, including hypothalamus, significantly increased the mean life span and decreased the development of age-related pathology in rats [94]. It was hypothesized that antidiabetic biguanides and possibly chromium picolinate, have regulate tyrosine hydroxylase and insulin/IGF-1 signaling pathway genes both associated with longevity [10,95,96]. It was shown that the polymorphism at TH-INS locus affects non-insulin dependent type 2 diabetes [97], and is associated with hypothalamic obesity [98], polycystic ovary syndrome [99], hypertriglyceridemia and atherosclerosis [100].

Anti-tumor Effects of Biguanides

Nowadays there are a burst of data on anti-tumor effects of biguanides both in vitro and in vivo [for review see: 45,69,101,102]. In this paper we shall not to discuss this aspect of the biguanides’ potential. However the capacity of the biguanides to prevent spontaneous and tumorigenesis induced by chemical carcinogens or ionizing irradiation will be briefly analyzed. Long-term treatment with phenformin significantly inhibited (by 4.0-fold, p < 0.01) the incidence of spontaneous mammary adenocarcinomas in female C3H/Sn mice [67]. The tumor yield curve rise was also significantly slowed down as a result of the treatment. The treatment with phenformin was followed by 1.6-fold decrease in total spontaneous tumor incidence in rats, whereas total tumor incidence was decreased by 49.5% in buformin-treated rats [73,74].

The anticarcinogenic effect of antidiabetic biguanides has been demonstrated in several models of induced carcinogenesis (Table 2).

Daily oral administration of phenformin or buformin suppressed 7,12-dimethylbenz(a)anthracene (DMBA)-induced mammary tumor development in rats [73,111,112]. Phenformin-treated rats revealed a tendency toward a decrease in serum insulin level. The treatment with phenformin normalised the tolerance to glucose and serum insulin and IGF-1 level in rats exposed to intravenous injections of N-nitrosomethylurea (NMU) and inhibited mammary carcinogenesis in these animals [113]. Treatment of rats with 1,2-dimethylhydrazine (DMH) (once a week during 4 weeks) caused the decrease in the level of biogenic amines, particularly, of dopamine in the hypothalamus, the decrease of glucose tolerance and the increase of the blood level of insulin and triglycerides. The exposure to DMH also caused the inhibition of lymphocyte blastogenic response to phytohemagglutinin and lipopolysaccharide, the decrease in the level of antibody produced against sheep erythrocytes and the decrease in phagocytic activity of macrophages [117]. Administration of phenformin started from the 1st injection of the carcinogen restored all the above mentioned immunological indices and inhibited DMH-induced colon carcinogenesis [117,118]. It is worthy to note that colon 38 adenocarcinoma growth was significantly inhibited in liver-specific IGF-1-deficient mice whereas injections with recombinant human IGF-1 displayed sufficiently promoted the tumour growth and metastasing [122].

A decrease of glucose utilisation in the oral glucose tolerance test was found in the 3-month-old female progeny of rats exposed to NMU on the 21st day of pregnancy [115]. The serum insulin level was not differ from the control, but the cholesterol level was higher in offspring of NMU-treated rats as compared with the control. Postnatal treatment with buformin started from the age of 2 months significantly inhibited the development of malignant neurogenic tumors in rats transplacentally exposed to NMU. Similar results have been observed in rats exposed transplacentally to N-nitrosothylurea (NEU) and postnatally to phenformin [116]. Authors observed the decrease of development of nervous system and renal tumors induced transplacentally with NEU. The treatment with phenformin inhibited also the carcinogenesis induced by a single total-body X-rays irradiation in rats [119].
Vinnitski and Iakumenko [103] have shown that treatment with phenformin increased the immunological reactivity and inhibited carcinogenesis induced by s.c. administration of 20-methylcholanthrene in BALB/c mice.

It was shown that metformin suppresses both azoxymethane-induced colorectal aberrant crypt foci [106] and lung carcinogenesis induced by tobacco carcinogen in mice [110]. It inhibits also benzo(a)pyrene-induced skin and cervico-vaginal carcinogenesis in mice [108,109].

In high fat-fed hamsters, the treatment with N-nitrosobis-(2-oxopropyl) amine was followed by the development of pancreatic malignancies in 50% of cases, whereas no tumors were found in the hamsters treated with the carcinogen and metformin [121].

The effects of new antidiabetic drug Diabenol® on spontaneous tumor incidence in NMRI and transgenic HER-2/neu mice as well as on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats are studied [71]. The treatment with diabenol inhibited spontaneous tumor incidence and increased the mammary

| Drug        | Carcinogen               | Main target(s)          | Effect   | References |
|-------------|--------------------------|-------------------------|----------|------------|
| **Mouse**   |                          |                         |          |            |
| Phenformin  | Spontaneous              | Mammary gland           | Inhibition| [67]       |
| Phenformin  | 20-methylcholanthrene    | Subcutaneous soft tissues| Inhibition| [103]  |
| Diabenol    | HER2/neu                 | Mammary gland           | Inhibition| [71]       |
| Metformin   | HER2/neu                 | Mammary gland           | Inhibition| [68,69]  |
| Metformin   | Spontaneous              | Mammary gland           | No effects| [70]       |
| Diabenol    | Spontaneous              | Mammary gland           | Inhibition| [71]       |
| Metformin   | Spontaneous, Apc<sup>Min−</sup> | Small intestines  | Inhibition| [104]  |
| Metformin   | Spontaneous, PTEN+/−     | Lymphoma, intestine     | Inhibition| [105]  |
| Phenformin  | Spontaneous, PTEN+/−     |                         | Inhibition|            |
| Metformin   | Azoxymethane             | Colon                   | Inhibition| [106]  |
| Metformin   | Estradiol, tamoxifen     | Endometrium             | Inhibition| [107]  |
| Metformin   | Benzo(a)pyrene           | Cervix uterus and vagina| Inhibition| [108]  |
| Metformin   | Benzo(a)pyrene           | Skin                    | Inhibition| [109]  |
| Metformin   | NNK                      | Lung                    | Inhibition| [110]  |
| **Rat**     |                          |                         |          |            |
| Buformin    | Spontaneous              | Total incidence         | Inhibition| [73,74]  |
| Phenformin  | Spontaneous              | Total incidence         | Inhibition| [73]    |
| Phenformin  | DMBA                     | Mammary gland           | Inhibition| [111,112]|
| Phenformin  | N-nitrosomethylurea      | Mammary gland           | Inhibition| [113]  |
| Buformin    | DMBA                     | Mammary gland           | Inhibition| [114]  |
| Buformin    | N-nitrosomethylurea, transplacentally | Nervous system    | Inhibition| [115]  |
| Phenformin  | N-nitrosothylene, transplacentally | Nervous system, kidney | Inhibition| [116]  |
| Phenformin  | 1,2-dimethylhydrazine    | Colon                   | Inhibition| [117,118]|
| Diabenol    | 1,2-dimethylhydrazine    | Colon                   | Inhibition| [71]     |
| Phenformin  | X-rays                   | Total incidence         | Inhibition| [119]  |
| Metformin   | N-nitrosomethylurea      | Mammary gland           | Inhibition| [120]  |
| **Hamster** |                          |                         |          |            |
| Metformin   | N-nitrosobis(2-oxopropyl)amine | Pancreas               | Inhibition| [121]  |

Abbreviations: DMH – 1,2-dimethylhydrazine; MCA – 20-methylcholanthrene; NBOPA -N-nitrosobis(2-oxopropyl)amine; NEU – N-nitrosothyleneurea; NMU – N-nitrosomethylurea; NNK – 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone; X-rays – total-body X-ray irradiation.
tumor latency in these mice. Diabenol treatment slowed down age-related changes in estrous function in HER-2/neu mice, failed influence survival of these mice and slightly inhibited the incidence and decreased the size of mammary adenocarcinoma metastases into the lung. In rats exposed to DMH, treatment with diabenol significantly inhibited multiplicity of all colon tumors, decreased by 2.2 times the incidence of carcinomas in ascending colon and by 3.1 times their multiplicity. Treatment with diabenol was followed by higher incidence of exophytic and well-differentiated colon tumors as compared with the control rats exposed to the carcinogen alone (76.3% and 50%, and 47.4% and 14.7%, respectively). Thus, antidiabetic drugs inhibits spontaneous and induced carcinogenesis in rodents.

**Antidiabetic Drugs and Cancer Risk in Human**

There are evidences that insulin resistance or some other aspect of type 2 diabetes may promote breast and some other cancers [39,123,124]. Biguanides were used as a component of the so-called metabolic rehabilitation of breast and colon cancer patients [39,55,56]. The total of 324 patients (182 with breast cancer and 142 with colon cancer) treated by surgery of the primary tumor were randomly divided into control and treatment groups. In the latter group, diet with reduction of saturated fats and cholesterol was complemented by biguanides or hypolipidemic drugs (mainly clofibrate in breast cancer patients). Among patients treated with biguanides 304 were given the drug more than 3 years and 15% more than 5 years. The authors reported an overall improvement in the cumulative survival by 3-6 and 4-7 years of observation in groups with breast and colon cancer, respectively, as well as a slight decrease in frequency of primary multiple neoplasms and metachronous tumors in the contralateral breast [39,55-61]. Evans et al. [125] reported results of a pilot case-control study on 11 876 diabetic patients treated or not treated with metformin. Authors collated information about use of metformin for all cases and controls and calculated unadjusted odds ratios of cancer risk using conditional logistic regression. More than a third (336; 36.4%) of the cases had been given at least on prescription of metformin in the year before their index date compared with 732 (39.7%) of the controls. The unadjusted odds ratio of cancer risk was estimated as 0.86 (95% confidential interval - 0.73 to 1.02). The unadjusted odds ratio for any exposure to the drug since 1993 was 0.79 (0.67 to 0.93). It is worthy to note that the authors suggested a dose-response relationship: adjusted odds ratio for patients dispensed total amount 14 - 672 g of metformin was 0.83 (0.65 to 1.06), dispensed 673 – 964 g of metformin – 0.86 (0.68 to 1.10) and dispensed more than 964 g - 0.57 (0.43 to 0.75).

In another study, cancer-related mortality was compared among inception cohorts of metformin users and sulfonylurea monotherapy users [126]. There were 10,509 new users of metformin or sulfonylurea with an average follow-up of 5.4 ± 1.9 years. Cancer mortality over follow-up was 4.9% (162 of 3,340) for sulfonylurea monotherapy users, and 3.5 (245 of 6,969) for metformin users (p = 0.01 for χ2 test) and 5.8 (84 of 1,443) for patients who used insulin. Multivariate adjustment has shown that the sulfonylurea cohort had greater cancer-related mortality compared with the metformin cohort (1.3 (95% CI 1.1-1.6); p = 0.012), whereas insulin use was associated with an adjusted cancer-related mortality of 1.9 (1.5 – 2.4; p < 0.0001). In a prospective study, it was found (after a median follow-up time of 9.6 years) that metformin use at baseline was associated with less cancer-related mortality [127]. 1 353 patients with type 2 diabetes were enrolled in the project. Of the patients, 570 died, of which 122 died of malignancies. The standardized mortality ratios (SMRs) for cancer mortality was 1.46 (95% CI 1.22 – 1.76). In patients taking metformin compared with patients not taking metformin at baseline, the adjusted hazard ration for cancer mortality was 0.43 (95% CI 0.23 – 0.80). Cochrane report stressed that there were either insufficient or no data on the relative efficacy of metformin for preventing the development of diabetes, cardiovascular disease, or endometrial cancer [128].

**Mechanisms of Effects of Biguanides on Aging and Cancer**

It is worthy to note that studies of metformin distribution in mice showed that 2 hour after a single oral dose of 14C metformin (150 mg/kg) there was a measurable accumulation of the drug in brain tissue [129]. It was shown that orally administered metformin increases brain AMPK activation [76]. This suggests that metformin crossed the blood-brain barrier and exert a pharmacological effect in intact brain.

Data on molecular mechanisms of inhibitory effect of biguanides on tumor growth have been discussed in several recent papers [49-51,101,102,130-137]. The formation and accumulation of advanced glycation end products (AGE) in various tissues are known to be involved in aging process and complications of long-term diabetes [36,37]. Effects of biguanides bufromin and metformin on AGE formation have been studied in vitro [138]. It was shown that both drugs are potent
inhibit metabolic immunodepression, which arises in the course of aging and specific age-related pathology [39,40]. If immunodepression is one of the important factors in carcinogenesis, then the elimination of metabolic immunodepression, which arises in the course of normal aging or under the influence of chemical carcinogens or ionizing radiation, can provide an anticarcinogenic prophylactic effect [1,39,40,117].

Although it is known that free radicals are produced during metabolic reactions, it is largely unknown which factor(s), of physiological or pathophysiological significance, modulate their production in vivo. It has been suggested that hyperinsulinemia may have increase free radicals and therefore promote aging, independent of glycemia [39,77,78,151,152]. Plasma levels of lipid hydroperoxides are higher, and antioxidant factors are lower in individuals who are resistant to insulin-stimulated glucose disposal but otherwise glucose tolerant, nonobese, and normotensive [77]. This finding indicates that enhanced oxidative stress is present before diabetes ensues and therefore cannot simply be explained by overt hyperglycemia. There is substantial evidence supporting the hypothesis that selective resistance to insulin-stimulated (muscle) glucose disposal and the consequential compensatory hyperinsulinemia trigger a variety of metabolic effects, likely resulting in accelerated oxidative stress and aging [39,77].

The antidiabetic biguanides inhibit fatty acid oxidation, gluconeogenesis in the liver, increase the availability of insulin receptors, decrease monoamine oxidase activity [53,54], increase sensitivity of hypothalamo-pituitary complex to negative feedback inhibition, and reduce excretion of glucocorticoid metabolites and dehydroepiandrosterone-sulfate [39]. These drugs have been proposed for the prevention of the age-related increase of cancer and atherosclerosis, and for retardation of the aging process [39,62]. It has been shown that administration of antidiabetic biguanides to patients with hyperlipidemia lowers the level of blood cholesterol, triglycerides, and b-lipoproteins. Biguanides also inhibits the development of atherosclerosis, reduces hyperinsulinemia in men with coronary artery disease. Its increases hypothalamo-pituitary sensitivity to inhibition by dexamethasone and estrogens, causes restoration of estrous cycle in persistent-estrous old rats, improves cellular immunity in atherosclerotic and cancer patients, lowers blood IGF-1 levels in cancer and atherosclerotic patients with type IIb hyperlipoproteinemia. Recently it was shown that metformin decreases platelet superoxide anion production in diabetic patients [153]. There are
sensitivity [28]. Deletion of immune and motor dysfunction and loss of insulin resistance to age-related pathologies, such as bone, signaling pathway, led to increased life span and responsive mTOR (mammalian target of rapamycin) [50]. Increased life span was observed in female (+20.4%) but it was not increased in male S6K1+/− mice. The mean life span of oldest 10% survivors and maximum life span were also conserved regulator of the metabolic response to CR [3,165]. It was worthy to note, the mean life span extension was observed in female (+20.4%) but it was not increased in male S6K1−/− mice. The mean life span of oldest 10% survivors and maximum life span were also increased only in females. There was no difference in the incidence of macroscopic tumors in S6K1+/− and wild type mice. The strain differences in susceptibility to metformin could also be a reason of variability in response to treatment. It was shown that mean strain-specific lifespan varied 2- to 3-fold under ad libitum feeding and 6- to 10-fold under dietary restriction in virgin males and females in 41 recombinant inbred strains of mice [159]. Notably, dietary restriction shortened life span in more strains than those in which it lengthened life. Food intake and female fertility varied markedly among strains under ad libitum feeding, but neither predicted dietary restricted mice survival. Therefore, strains in which dietary restriction shortened life spans did not have low food intake or poor reproductive potential. These results demonstrate that life extension by dietary restriction may not be universal.

CONCLUSION

The striking similarities have been described between insulin/IGF-1 signaling pathways in yeast, worms, flies, and mice [10]. Many characteristics of mice that are long lived due to genetic modifications resemble effects of caloric restriction in wild-type (normal) animals. Comparison of characteristics of exposed to these endogenous and exogenous influences shows a number of similarities but also some differences. Effects of antidiabetic biguanides seems to be more adequate in the prevention of age-related deteriorations in glucose metabolism and in insulin signaling pathway as well as in such important for longevity parameters as fertility and a resistance to oxidative stress and tumorigenesis than those induced by caloric restriction and genetic manipulations. It was recently demonstrated by Ligibel et al. [160] that a physical activity program significantly lowers insulin levels raises the intriguing possibility that lifestyle intervention may act as a targeted therapy in breast cancer. Metformin use in diabetic patients has been associated with reduced cancer incidence and mortality in the number of population-based studies. Furthermore, there is evidence that metformin may have insulin independent direct effects of cancer cells, acting as a mammalian target of rapamycin (mTOR inhibitor) [101,102,131-137,161-163]. It was suggested that this dual action of metformin (insulin reduction inhibitor) makes it a particularly attractive target for evaluation in breast cancer [50,51,101,102,161,164] as well as some other, e.g. colon cancer. It remains to be shown that either antidiabetic biguanides can extend life span independently of CR [3,165].

ACKNOWLEDGEMENTS

This article was supported in part by grant 08-04-01116-a from Russian Foundation for Basic Research.

CONFLICT OF INTERESTS STATEMENT

The author declares no conflict of interests.
REFERENCES

1. Anisimov VN. Carcinogenesis and Aging. Vol 2. Boca Raton, FL. CRC Press. 1987.
2. Anisimov VN. Premature ageing prevention: Limitations and perspectives of pharmacological interventions. Current Drugs Targets. 2006; 7: 1485-1503.
3. Spindler SR. Caloric restriction: From soup to nuts. Ageing Res Rev. 2010; 9: 324-353.
4. Anisimov VN. Carcinogenesis and aging 20 years after: escaping horizon. Mech Ageing Dev. 2009; 130: 105-121.
5. Weindruch R and Walford R. The Retardation of Aging and Disease by Dietary Restriction. Springfield, Ill.: C.C. Thomas. 1988.
6. Masoro EJ. Caloric restriction and aging, controversial issues. J Gerontol Biol Sci. 2006; 61A: 14-19.
7. Barzilai N and Bartke A. Biological approaches to mechanistically understand the healthy life span extension achieved by calorie restriction and modulation of hormones. J Gerontol A Biol Sci Med Sci. 2009; 64: 187-191.
8. Roth GS, Ingram DK, and Lane M.A. Calorie restriction in primates, will it work and how will we know? J Am Geriatr Soc. 1999; 46: 869-903.
9. Mattson JA, Lane MA, Roth GS, and Ingram DK. Calorie restriction in rhesus monkeys. Exp Gerontol. 2003; 38: 35-46.
10. Kenyon C. A conserved regulatory system for aging. Cell 2001; 105: 165-168.
11. Ingram DK, Zhu M, Mamczarz J, Zou S, Lane MA, Roth GS, and deCabo R. Calorie restriction mimetics: an emerging research field. Aging Cell 2006; 5: 97-108.
12. Weindruch R. Will dietary restriction work in primates? Biogerontology 2006; 7: 169-171.
13. Braekman BP, Demetrius L, and Vandflieteren JR. The dietary restriction effect in C. elegans and humans: is the worm a one-millimeter human? Biogerontology 2006; 7: 127-133.
14. Goto S. Health span extension by later-life caloric or dietary restriction: a view based on rodent studies. Biogerontology 2006; 7: 135-138.
15. Le Bourg E. Dietary restriction would probably not increase longevity in human being and other species able to leave unsustainable environments. Biogerontology 2006; 7: 149-152.
16. Mockett RJ, Cooper TM, Orr WC, and Sohal RS. Effects of caloric restriction are species-specific. Biogerontology 2006; 7: 157-160.
17. Shanley DP and Kirwood TBL. Caloric restriction does not enhance longevity in all species and is unlikely to do so in humans. Biogerontology 2006; 7: 165-168.
18. Willcox DC, Willcox BJ, Todoriki H, Curb JD and Suzuki M. Caloric restriction and human longevity: what can we learned from the Okinawians? Biogerontology 2006; 7: 173-177.
19. Yu BP. Why caloric restriction would work for human longevity. Biogerontology 2006; 7: 179-182.
20. Tatar M, Koppelman A, Epstein D, Tu MP, Yin CM, and Garofalo RS. A mutant Drosophila insulin receptor homolog that extends life-span and impairs neuroendocrine function. Science 2001; 292: 107-110.
21. Lund J, Tedesco P, Duke K, Wang J, Kim SK, and Johnson TE. Transcriptional profile of aging in C. elegans. Curr Biol. 2002; 12: 1566-1573.
22. Pinkston-Gosse J and Kenyon C. DAF-16/ FOXO targets genes that regulate tumor growth in Caenorhabditis elegans. Nat Genet. 2007; 39:1306-1307.
23. Pinkston-Gosse J, Gaigan D, Hansen M and Kenyon C. Mutations that increase the life span of C. elegans inhibit tumor growth. Science 2006; 313: 971-975.
24. Lee SS, Kennedy S, Tolonen AC, and Ruvkun G. DAF-16 target genes that control C. elegans life-span and metabolism. Science 2003; 300: 644-647.
25. Tatar M, Bartke A and Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003; 299: 1346-1351.
26. Taguchi A, Wartschow LM, White MF, and Brain IRS2 signaling coordinates life span and nutrient homeostasis. Science 2007; 317: 369-372.
27. Kapeller L, De Magalhaes Filho C, Dupont J, Leneuve P, Cervera P, Perin L, Loudes C, Blaise A, Kleine R, Eipelbaum J, Le Bouc Y, and Holzenberger M. Brain IGF-1 receptors control mammalian growth and life span through a neuroendocrine mechanism. PLoS Biol2008; 6(10), e254. doi:10.1371/journal.pbio.0060254.
28. Selman C, Tullet JA, Wieser D, Irvine E, Lingard SJ, Choudhury AI et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326: 140-144.
29. Anisimov SV, Volkova MV, Lenskaya LV, Khavinson VKh, Solovieva DV, and Schwartz EI. Age-associated accumulation of the Apolipoprotein C-III gene T-455C polymorphism C allele in a Russian population. J Gerontol Biol Sci. 2001; 56A: B27-B32.
30. Paolisso G, Gambardella A, Amodena S, D’Amore A, and Varrichio M. Glucose tolerance and insulin action in healthy centenarians. Am J Physiol. 1996; 270: E890-E896.
31. Barbieri M, Rizzo MR, Manzelii D et al. Glucose regulation and oxidative stress in healthy centenarians. Exp Gerontol. 2003; 38: 137-143.
32. Singal PK, Beamish RE, and Dhalia NS. Potential oxidative pathways of catecholamine in the formation of lipid peroxides and genesis of heart disease. Adv Exp Biol Med. 1983; 161: 391-401.
33. Ruiz-Torres A, and Soares de Melo Kirzner M. Ageing and longevity are related to growth hormone/insulin-like growth factor-1 secretion. Gerontology 2002; 48: 401-407.
34. Roth GS, Lane MA, Ingram DK et al. Biomarkers of caloric restriction may predict longevity in humans. Science 2002; 297: 811.
35. Van Heemst D, Beekman M, Mooijaart SP et al. Reduced insulin/insulin-like signaling and human longevity. Aging Cell 2005; 4: 79-85.
36. Ulrich P, and Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001; 56: 1-21.
37. Facchin FD, Hua NW, Reaven GM, and Stoohe R. Hyperinsulinemia, the missing link among oxidative stress and age-related diseases? Free Radicals Biol Med. 2000; 29: 1302-1306.
38. Facchin FD, Humphreys MH, Abbasi F, DoNascimento CA, and Reaven GM. Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am J Clin Nutr. 2000; 72:776-779.
39. Dilman VM. Development, Aging and Disease. A New Rationale for an Intervention. Chur: Harwood Academic Publishers 1994.
40. Dilman VM. Ageing, metabolic immunodepression and carcinogenesis. Mech Ageing Dev. 1978; 8: 153-173.
41. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, and Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev. 2002; 11: 385-391.
42. Gupta K, Krishnaswamy G, Karnad A, and Peiris AN. Insulin: a novel factor in carcinogenesis. Am J Med Sci. 2002; 323:140–145.
43. Pollak MN, Schernhammer ES, and Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4:505–518.
44. Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res. 2007; 174: 49-53.
45. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res. 2010; 3: 1060-1065.
46. Hadley EC, Dutta C, Finkelstein J, Harris TB, Lane MA, Roth GS, Sherman SS, and Starke-Reed PE. Human implications of caloric restriction’s effect on laboratory animals: an overview of opportunities for research. J Gerontol Ser A. 2001; 56A (Special issue I):5–6.
47. Weindruch R, Keenan, KP, Carney JM et al. Caloric restriction mimetics, metabolic intervention. J Gerontol Biol Sci. 2001; 56A, Special Issue 1: 20-33.
48. Blagosklonny MV. Aging and immortality. Quasi-programmed senescence and its pharmacological inhibition. Cell Cycle 2006; 5: 2087-2102.
49. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discovery Today 2007; 12: 218-224.
50. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther. 2008; 7:1520-1524.
51. Blagosklonny MV. Validation of anti-aging drugs by treating age-related diseases. Aging 2009;1:281-288.
52. Longo VD, and Finch CE. Evolutionary medicine, from dwarf model systems to healthy centenarians? Science 2003; 299: 1342-1346.
53. Muntoni S. Inhibition of fatty acid oxidation by biguanides, implication for metabolic physiopathology. Adv Lipid Res 1974; 12: 311-77.
54. Muntoni S. Metformin and fatty acids. Diabetes Care 1999; 22: 179-80.
55. Dilman VM, Berstein LM, Ostroumova MN et al. Metabolic immunodepression and metabolic immunotherapy, an attempt of improvement in immunologic response in breast cancer patients by correction of metabolic disturbances. Oncology 1982; 39: 13-19.
56. Dilman VM, Berstein LM, Yevtushenko TP et al. Preliminary evidence on metabolic rehabilitation in cancer patients. Arch Geschwulstforsch. 1988; 58: 175-183.
57. Berstein LM, Evtushenko TP, Tsyrlina EV et al. Comparative study of 5- and 10-year-long results of the metabolic rehabilitation of cancer patients. In, Neuroendocrine System, Metabolism, Immunity and Cancer (Clinical Aspects); Hanson KP, Dilman VM, Eds; N.N. Petrov Research Institute of Oncology Publ: St-Petersburg, 1992, pp 102-112.
58. Berstein LM, Kvatchevskaya JuO, Poroshina TE et al. Insulin resistance, its consequences for clinical course of the disease and possibilities of correction in endometrial cancer. J Cancer Res Clin Oncol. 2004; 130: 687-693.
59. Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett. 2005; 224: 203-12.
60. Berstein LM. 2010. Modern approach to metabolic rehabilitation of cancer patients: biguanides (phenformin and metformin) and beyond. Future Oncol. 2010; 6: 1313-1323.
61. Berstein LM. 2010a. Biguanides: An Expansion to Practical Oncology (past and present).- St.Petersburg: Aesclapul, 144 p.
62. Dilman VM. Age-associated elevation of hypothalamic threshold to feedback control and its role in development, aging and disease. Lancet 1971; 1: 1211-9.
63. Bakaev VV. Effect of 1-butylbiguanide hydrochloride on the longevity in the nematoda Caenorhabditis elegans. Biogerontology 2002; 3, Suppl. 1: 23-24.
64. Onken B, and Driscoll M. Metformin induces dietary restriction-like state and the oxidative stress response to extend C. elegans healthspan via AMPK, LKB1, and SKN-1. PloS ONE 5(1): e8758. doi:10.1371/journal.pone.0008758
65. Zhou G, Myers R., Li Y, Chen Y, Shen X, Fenyk-Melody J et al. Role of AMP-activated protein kinase in metvhaism of metformin action. J Clin Invest. 2001; 108:1167-1174.
66. Shaw RJ, Lamia KA, Vasquez D, Koo S-H, Bardeesy N, DePinho RA, Montminy M, and Cantley LC. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005; 310: 1642-1664.
67. Dilman VM, and Anisimov VN. Effect of treatment with phenformin, dychenylhydrantoin or L-DOPA on life span and tumor incidence in C3H/Sn mice. Gerontologist 1980; 26:241–245.
68. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhtinski MA, Kovalenko IG, Poroshina TE, Semenchkeno AV, Provinciali M, Re F, and Franceschi C. Effect of metformin on life span and on the development of spontaneous mammy tumors in HER-2/neu transgenic mice. Exp Gerontol. 2005; 40:685-693.
69. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MV, Zabezhtinski MA, Anikin IV, Karkach AS, and Romanyukha AA. Metformin extends life span of HER-2/neu transgenic mice and in combination with melanin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9: 188-197.
70. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhtinski MA, Tyndyk ML, Yurova MN, Kovalenko IG, Poroshina TE, and Semenchenko AV. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008; 7:2769-2773.
71. Popovich IG, Zabezhtinski MA, Egormin PA, Tyndyk ML, Anikin IV, Spasov AA, Semenchenko AV, and Anisimov VN. Insulin in aging and cancer: new antidiabetic drug Diabenol as geroprotector and anticarcinogen. Int J Biochem Cell Biol. 2005; 37:1117-1129.
72. Anisimov VN, Piskunova TS, Popovich IG, Zabezhtinski MA, Tyndyk ML, Egormin PA, Yurova MN, Rosenfeld SV, Semenchenko AV, Berstein LM, Kovalenko IG, and Poroshina TE. Protective effect of metformin on biomarkers of aging, life span and spontaneous tumorigenesis in female but not in male 129/Sv mice, in preparation.
73. Anisimov VN, Semenchenko AV, and Yashin AI. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology 2003; 4:297–307.
74. Anisimov VN. Effect of buformin and diphenylhydantoin on life span, estrus function and spontaneous tumor incidence in female rats. Vopr Onkol. 1980; 6: 42-48.
75. Smith DL, Elam CF, Mattison JA., Lane M.A., Roth GS, Ingram DK. and Allison DB. Metformin supplementation and life span in Fischer-344 rats. J Gerontol Biol Sci. 2010;65A: 468-474.
76. Ma TC, Buescher JL, Oatis B, Funk JH, Nash AJ, Carrier RL, and Hoyt KR. Metformin therapy in a transgenic mouse model of Huntington’s disease. Neurosci Lett. 2007; 411: 98-103.
77. Spasov AA, Dudchenko GP, and Gavrilova E.S. Diabenol – new anti-diabetic compounds with haemobiological activity. Vestnik Volgograd Med Acad. 1997; 2: 47-51.
78. Anisimova VA, Osipova VV, and Spasov AA. Synthesis and pharmacological activity of 1- and 10-N-substituted 1(10),2,3,4-tetrahydropyrimido[1,2-a]benzimidazoles. Chemico-Pharmaceut J. 2002; 9: 11-16.
79. Spasov AA, Ostrovskii OV, Ivakhnenko IV, Kosolapov VA, and Anisimova VA. The effect of compounds with antioxidiant properties on thrombocyte functional activity. Eksp Klin Farmakol (Moscow) 1995; 1: 38-40.
80. Zinovieva VN, Ostrovskii OV, Anisimova VA, and Spasov AA. Benzimidazole derivative inhibition of the mutagenic activity of 2-aminoanthracene. Gig Sanit. 2003; 5:61-63.
81. Scarpello JH. Improving survival with metformin, the evidence base today. Diabetes Metab. 2003; 29: 5636-5643.
82. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, and Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005; 28: 2345-2351.
83. Anisimov VN, Popovich IG, and Zabezhinski MA. Methods of evaluating the effect of pharmacological drugs on aging and life span in mice. Methods Mol Biol. 2007; 371: 227-236.
84. Anisimov VN, and Dilman VM. The increase of hypothalamic sensitivity to the inhibition by estrogens induced by the treatment with L-DOPA, diphenyl-hydantoin or phenformin in old rats. Bull Exp Biol Med. 1975; 11: 96-98.
85. Dilman VM, and Anisimov VN. Hypothalamic mechanisms of ageing and of specific age pathology – I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system. Exp Gerontol. 1979; 14: 161-174.
86. Rossmanith WG. Neuroendocrinology of aging in the reproductive system, gonadotropin secretion as an example. In: Follicular Gowerth, Ovulation and Fertilization, Molecular and Clinical Basis. Kumar A, Mukhopadhayay AK, Eds, Narosa Publ House: New Delhi. 2001, pp 15-25.
87. Hung AJ, Stanbury MG, Shanabrough M, Horvath TL, Garcia-Segura LM, and Naftolin F. Estrogen, synaptic plasticity and hypothalamic reproductive aging. Exp Gerontol. 2003; 38: 53-59.
88. Awartani KA and Cheung AP. Metformin and polycystic ovarian syndrome, a literature review. J Obstet Gynecol Can 2002; 24: 393-401.
89. Nestler JE, Stovall D, Akthner N, Iorno MJ, and Jakubowicz DJ. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome, Fertil Steril. 2002; 77: 209-215.
90. Fernandes ML, Saad MJ, and Velloso LA. Effect of age on elements of insulin-signaling pathway in central nervous system of rats. Endocrine 2001; 16: 227-234.
91. Richards JS, Russell DL, Ochsner S et al. Novel signaling pathways that control ovarian follicular development, ovulation, and luteinization. Recent Prog Horm Res. 2002; 57: 195-220.
92. Chiba T, Yamaza H, Higami Y, and Shimokawa I. Anti-aging effects of caloric restriction, Involvement of neuroendocrine adaptation by peripheral signaling. Microsc Res Tech. 2002; 59: 317-324.
93. Mattson MP, Duan W, and Maswood N. How does the brain control lifespan? Ageing Res Rev. 2002; 1: 155-165.
94. McCarty MF. Longevity effect of chromium picolinate – ‘rejuvenation’ of hypothalamic function? Medical Hypotheses 1994; 3: 253-65.
95. De Benedictis G, Carotenuto L, Carieri G et al. Gene/longevity association studies at four autosomal loci (REN, THO, PARP, SOD2). Eur J Human Gen. 1998; 6: 534-541.
96. De Benedictis G, Tan Q, Jeune B et al. Recent advances in human gene-longevity association studies. Mech Ageing Dev. 2001; 122: 909-920.
97. Huxtable SJ, Saker PJ, Haddad L et al. Analysis of parent-offspring trios provides evidence for linkage and association between the insulin gene and type 2 diabetes mediated exclusively through paternally transmitted class III varable number tandem repeat alleles. Diabetes 2000; 49: 126-130.
98. Weaver JU, Kopelman PG, and Hiltman GA. Central obesity and hyperinsulinemia in women are associated with polymorphism in the 5’ flanking region of the human insulin gene. Eur J Clin Invest. 1992; 22: 265-270.
99. Waterworth DM, Bennett ST, Gharani N et al. Linkage and association of insulin gene VNTR regulatory polymorphsim with polycystic ovary syndrome. Lancet 1997; 349: 986-990.
100. Tybaierg-Hansen A, Gerdes IU, Overgaard K, Ingerslev J, Faergeman O, and Nerup J. Polymorphism in 5’ flanking region of human insulin gene. Relationships with atherosclerosis, lipid levels and age in three samples from Denmark. Arteriosclerosis 1990; 10: 372-378.
101. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraro C, and Menendez JA. Metformin and cancer. Doses, mechanisms and the dandelion and hermetic phenomena. Cell Cycle 2010; 9: 1057-1064.
102. Vazquez-Martin A, Oliveras-Ferraro C, Cufi S, Martin-Castillo B, and Menendez JA. Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. Curr Mol Med. 2010; 10:674-691.
103. Viinitski VB, and Iakimenko VA. Effect of phenformin, L—DOPA and para-chlorophenylalanine on the immunological reactivity and chemical carcinogenesis in BALB/c mice. Vopr Onkol. 1981; 27: 45-50.
104. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H, and Nakajima A. Metformin suppresses intestinal polyp growth in Apc<del+> mice. Cancer Sci. 2008; 99: 2136-2141.
105. Huang X,ULLscheleger S, Shiipo N, McGuire VA, Sakaoto K, Woods YL, McBurnie W, Fleming S, and Alessi DR. Important role of the LKB1-AMPK pathway in suppressing tumorgenesis in PTEN-deficient mice. Biochem J. 2008; 412:211-221.
106. Hosono K., Endo H, Takahashi H, Sugiyama M, Uchiyama T, Suzuki K, Nozaki Y, Yoneda K, Fujita K, Yoneda M, Inamori M, Tomatsu A, Chihara T, Shimpo K, Nakagama H, and Nakajima A. Metformin suppresses azoxy methane-induced colorectal
aberrant crypt foci by AMP-activating protein kinase. Mol Carcinogenesis 2010; 49: 662-671.

107. Erdemoglu, E, Güney M, Giray SG, Take G, and Mungan, T. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2009; 145: 195-199.

108. Deriabina ON, Plotnikova NA, Kharitonova TV, Kirichenko EV, Soldatov OM, Pashkevich IV, and Anisimov VN. Melatonin and metformin inhibits development of cervico-vaginal tumors induced by benzo(a)pyrene in mice. Morphol. Vedomosti, 2010, in press.

109. Deriabina ON, Plotnikova NA, and Anisimov VN. Melatonin and metformin inhibits skin carcinogenesis induced by benzo(a)pyrene in mice. Vopr Onkol. 2010; 56: 583-587.

110. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, and Dennis P. Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res. 2010; 3: 1066-1076.

111. Dilman VM, Berstein LM, Zabezhinski MA, and Alexandrov VA. On effect of phenformin on induction of mammary gland tumors in rats. Vopr. Onkol. 1974; 20: 94-97.

112. Dilman VM, Berstein LM, Zabezhinski MA, Alexandrov VA, and Pliss GB. Inhibition of DMB-induced carcinogenesis by phenformin in the mammary gland of rats. Arch. Geschwlustforsch.1978; 48: 1-8.

113. Anisimov VN, Belous NM, Vasilyeva IA, and Dilman VM. Inhibitory effect of phenformin on the development of mammary tumors induced by N-nitrosomethyleurea in rats. Exp Onkol. 1980; 3: 40-43.

114. Anisimov VN, Ostroumovna MN, and Dilman VM. Inhibition of blastomagenic effect of 7,12-dimethylbenz(a)-anthracene in female rats by buformin, diphenylhydantoin, polypeptide pience extract and L-DOPA. Bull Exp Biol Med. 1980; 89: 723-725.

115. Alexandrov VA, Anisimov VN, Belous NM, Vasilyeva IA, and Mazon V.B. The inhibition of the transplacental blastomagenic effect of nitrosomethyleurea by postnatal administration of buformin to rats. Carcinogenesis 1980; 1: 975-978.

116. Bopalav VG, and Alexandrov VA. Influence of anti-carcinogenic agents on the transplacental carcinogenic effect of N-nitroso-N-ethylurea. Bull Exp Biol Med. 1985; 100:73-76.

117. Dilman VM, Sofronov BN, Anisimov VN, Nazarov PG, and L'vovich EG. Phenformin elimination of the immunodepression caused by 1,2-dimethylhydrazine in rats. Vopr Onkol. 1977; 23: 50-54.

118. Anisimov VN, Pozharisski KM, and Dilman VM. Effect of phenformin on the blastomagenic action of 1,2-dimethylhydrazine in rats. Vopr Onkol. 1980; 26 (8): 54-58.

119. Anisimov VN, Belous NM, and Prokudina EA. Inhibition by phenformin of the radiation carcinogenesis in female rats. Exp Onkol. 1982; 4 (6): 26-29.

120. Bojkova B, Orendas P, Garajova M, Kassayova M, Kutna V, Ahlersova E, and Ahlers I. Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 2009; 56:269-274.

121. Schneider MB, Matsu H, Harahor J, Uhrich A, Standl J, Ding XZ, Adrian TE, and Pour PM. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology 2001; 120: 1263–1270.

122. Wu Y, Yakar S, Zhao L, Hennighausen L, and LeRoith D. Circulating insulin-like growth factor-1 levels regulate colon cancer growth and metastasis. Cancer Res. 2002; 62: 1030-1035.

123. Saydah SH, Loria CM, Eberhardt MS, and Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol. 2003; 157: 1092-1100.

124. Lipscombe LL, Goodwin PJ, Ziman B, McLaughlin JR, and Huz JE. Diabetes mellitus and breast cancer, a retrospective population-based cohort study. Breast Cancer Res Treat. 2006; 98: 349-356.

125. Evans JM, Donnelly LA, Emslie-Smith, Alessi DR, and Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330:1304-1305.

126. Bowker SL, Majumdar SR, Veugelers P, and Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylurea or insulin. Diabetes Care 2006; 29:254-258.

127. Landman GWD, Klefstra N, van Hateren KJ, Groenier KH. Gans ROB and Bilo HJG. Metformin associated with lower cancer mortality in type 2 diabetes. Diabetes Care 2010; 33: 322-326.

128. Costello M, Shreshtha B, Eden J, Sjoblom P and Johnson N. Insulin-sensitizing drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. 2007; Jan 24; 1:CD005552.

129. Beckman R. Biguanide (Experimental Teil), in: H.Maske (Ed.), Handbook of Experimental Pharmacology, vol. 29. Berlin: Springer-Verlag, 1971, pp. 439-596.

130. Wysocki PJ, and Wierus-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn. 2010; 10: 509-519.

131. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, and Thor AD. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009; 8:909-915.

132. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE, and Thor AD. Metformin induces unique biological and molecular responses in triple negative breast cancer cells.Cell Cycle. 2009; 8:2031-2040.

133. Vazquez-Martín A, Oliveras-Ferraro C, del Barco S, Martin-Castillo B, and Menendez JA. The anti diabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol. 2009; 20:592-595.

134. Vazquez-Martín A, Oliveras-Ferraro C, and Menendez J.A. The anti diabtic drug metformin suppresses HER2 (erbB-2) oncprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009; 8:88-96.

135. Vucicic I, Misirkic K, Janjetovic K, Harhaji-Trajkovic L, Prca M, Stevanovic D, Isenovic E, Suder E, Sumarac-Dumanovic M, Micic D, and Trajkovic V. AMP-activated proteinkinase-dependent and –independent mechanisms underlying in vitro antiangioma action of compound C. Biochem Pharmacol. 2009; 77:1684-1693.

136. Zakikhani M, Dowling R, Fantus IG et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66: 10269-10273.
137. Zhuang Y, and Miskimins WK. Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signaling. 2008; 3:18 doi:10.1186/1750-2187-3-18.

138. Kho T, Kato M, Usui S, and Hirano K. Effect of buforin and metformin on formation of advanced glycation end products by methylglyoxal. Clinica Chimica Acta 2005; 358: 139-145.

139. Diamanti-Kandarakis E, Alexandraki K, Pippi C, Aessopos A, Paterakis T, Katsikis T, and Panidis D. Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. Metabolism 2007; 56: 129-134.

140. Nedosugova LV, Lankin VZ, Reznik SM et al. Effect of metformin on oxidative stress rate in type 2 diabetic patients. Probl Endocrinol. 2007; 53: 3-7.

141. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, and Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275: 223-228.

142. Owen MR, Doran E, and Halestrap AP. Evidence that metformin exerts it anti-diabetic effects through inhibition of complex I of the mitochondrial respiratory chain. Biochem J. 2000; 348: 607-614.

143. Brunmair B, Stainiek K, Grad F et al. Thiazolidinediones, like metformin, inhibit respiratory complex I. Diabetes 2004; 53: 1052-1059.

144. Aleisa AM, Al-Rejaie SS, Bakheer SA, Al-Bekari AM, Al-Shabanah OA, Al-Majed A, Al-Yahya AA, and Qureshi S. Effect of metformin on clastogenic and biochemical changes induced by Adriamycin in Swiss albino mice. Mutat Res. 2007; 634: 93-100.

145. Holland W, Morrison T, Chang Y, Wiensperger N, and Stith BJ. Metformin (Glicophagel) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004; 67: 2081-2091.

146. Fulgencio JP, Kohl C, Girard J, and Pégorier JP. Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes. Biochem Pharmacol. 2001; 62: 439-446.

147. Heishi M, Ichihara J, Teramoto R et al. Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin. Diabetologia 2006; 49: 1647-1655.

148. Kalender A., Selvaraj A, Kim SY, Guiliat P, Brule S, Violet B, Kemp BE, Bardeesy N, Dennis JJ, Schlager JJ, Marette A, Kozma SC, and Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a Rag GTPase-dependent manner. Cell Metab. 2010; 11: 390-401.

149. Spindler SR. Use of microarray biomarkers to identify longevity therapeutics. Aging Cell 2006; 5: 39-50.

150. Dhabbi JM, Mote PL, Fahy GM, and Spindler SR. Identification of potential restriction mimetics by microarray profiling. Physiol Genomics 2005; 23:343-350.

151. Anisimov VN. Insulin/IGF-1 signaling pathway driving aging and cancer as a target for pharmacological intervention. Exp Gerontol. 2003; 38: 1041-1049.

152. Facchinii FS, Hua N, Abbasi F, and Reaven GM. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab. 2001; 86: 3574-3578.

153. Gargiulo P, Caccese D, Pignatelli P et al. Metformin decreases platelet superoxide anion production in diabetic patients. Diabetes Metab Res Rev 2002; 18:156–159.

154. Solano ME, Sander V, Wald MR, and Motta AB. Dehydroepiandrosterone and metformin regulateproliferation of murine T-lymphocytes. Clin. Exp. Immunol. 2008: 153: 289-296.

155. Morales A.I., Detaille D., Prieto M. et al. Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway. Kidney Int. 2010; 77: 861-869.

156. Zorov DB. Amelioration of aminoglycoside nephrotoxicity requires protection of renal mitochondria. Kidney Int. 2010; 77: 841-843.

157. Attia SM, Helal GK, and Alhaider AA. Assessment of genomic instability in normal and diabetic rats treated with metformin. Chem-Biol Interact. 2009; 180: 296-304.

158. Diamanti-Kandarakis E, Kouri C, Tsianateli T, and Bergliea G. Therapeutic effect of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998; 138: 269-274.

159. Liao CY, Rikke BA, Johnson TE, Diaz V, and Nelson JF. Genetic variation in the murine lifespan response to dietary restriction: from life extension to life shortening. Aging Cell 2010; 9:92-95.

160. Libibel JA, Campbell N, Partridge A et al. Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J Clin Oncol. 2008; 26: 907-912.

161. Goodwin PA. Insulin in the adjuvant breast cancer setting: A novel therapeutic target for lifestyle and pharmacologic interventions? J Clin Oncol. 2008; 26: 833-834.

162. Oliveras-Ferraros C, Vazquez-Martin A, and Menendez JA. Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle. 2009; 8:1633-1636.

163. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, Tran H, Ross SE, Mostoslavsky R, Cohen HY, Hu LS, Cheng HL, Jedyrchowski MP, Gygi SP, Sinclair DA, Alt FW, and Greenberg ME. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science. 2004; 303: 2011-2015.

164. Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S, and Blandino G. Metformin, diet and breast cancer: an avenue for chemoprevention.Cell Cycle 2009; 8:2661.

165. Mouchiroud L, Molin L, Dalliere N, and Solari F. Life span extension by resveratrol, rapamycin, and metformin: The promise of dietary restriction mimetics for an healthy aging. Biofactors. 2010; 36: 377-392.